Regeneron wins FDA approval for first treatment of rare bone-forming disease

The FDA cleared Regeneron's garetosmab, an antibody targeting activin A, for fibrodysplasia ossificans progressiva, a condition where muscle and connective tissue progressively turn to bone. This marks the first approved therapy for the debilitating disorder.